|
1
|
Gu Y, Liu S, Zhang X, Chen G, Liang H, Yu
M, Liao Z, Zhou Y, Zhang CY, Wang T, et al: Oncogenic miR-19a and
miR-19b co-regulate tumor suppressor MTUS1 to promote cell
proliferation and migration in lung cancer. Protein Cell.
8:455–466. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deng L, Tang Y, Lin J, Lu XJ, Xue JX, Wang
LS, Zhou L, Zou Y, Ying BW, Li GD and Lu Y: Detection of epidermal
growth factor receptor gene mutation in non-small cell lung cancer
by allele-specific oligonucleotide-PCR and bi-loop probe specific
primer quantitative PCR. Zhonghua Bing Li Xue Za Zhi. 41:20–22.
2012.(In Chinese). PubMed/NCBI
|
|
3
|
Lo Russo G, Proto C and Garassino MC:
Afatinib in the treatment of squamous non-small cell lung cancer: A
new frontier or an old mistake? Transl Lung Cancer Res. 5:110–114.
2016.PubMed/NCBI
|
|
4
|
Kazandjian D, Suzman DL, Blumenthal G,
Mushti S, He K, Libeg M, Keegan P and Pazdur R: FDA approval
summary: Nivolumab for the treatment of metastatic non-small cell
lung cancer with progression on or after platinum-based
chemotherapy. Oncologist. 21:634–642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Antonia S, Goldberg SB, Balmanoukian A,
Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel
JJ and Rizvi NA: Safety and antitumour activity of durvalumab plus
tremelimumab in non-small cell lung cancer: A multicentre, phase 1b
study. Lancet Oncol. 17:299–308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou YY, Hu ZG, Zeng FJ and Han J:
Clinical profile of cyclooxygenase-2 inhibitors in treating
non-small cell lung cancer: A meta-analysis of nine randomized
clinical trials. PLoS One. 11:e0151932016.
|
|
7
|
Fenchel K, Sellmann L and Dempke WC:
Overall survival in non-small cell lung cancer-what is clinically
meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
|
|
8
|
Wang W, Zhang L, Wang Y, Ding Y, Chen T,
Wang Y, Wang H, Li Y, Duan K, Chen S, et al: Involvement of miR-451
in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Cell Death Dis. 8:e30712017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu D, Lu P, Mi X and Miao J:
Downregulation of mir-503 contributes to the development of drug
resistance in ovarian cancer by targeting pi3k p85. Arch Gynecol
Obstet. 297:699–707. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He L, Luo L, Zhu H, Yang H, Zhang Y, Wu H,
Sun H, Jiang F, Kathera CS, Liu L, et al: FEN1 promotes tumor
progression and confers cisplatin resistance in non-small-cell lung
cancer. Mol Oncol. 11:640–654. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang PF, Sheng LL, Wang G, Tian M, Zhu
LY, Zhang R, Zhang J and Zhu JS: miR-363 promotes proliferation and
chemo-resistance of human gastric cancer via targeting of FBW7
ubiquitin ligase expression. Oncotarget. 7:35284–35292. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krevvata M, Shan X, Zhou C, Dos Santos C,
Habineza Ndikuyeze G, Secreto A, Glover J, Trotman W, Brake-Silla
G, Nunez-Cruz S, et al: Cytokines increase engraftment of human
acute myeloid leukemia cells in immunocompromised mice but not
engraftment of human myelodysplastic syndrome cells. Haematologica.
103:959–971. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nasiri M, Karimi MH, Azarpira N and Saadat
I: Gene expression profile of toll-like receptor/adaptor/interferon
regulatory factor/cytokine axis during liver regeneration after
partial ischemia-reperfusion injury. Exp Clin Transplant.
2018.(Epub ahead of prin). PubMed/NCBI
|
|
16
|
Jiang YX, Yang SW, Li PA, Luo X, Li ZY,
Hao YX and Yu PW: The promotion of the transformation of quiescent
gastric cancer stem cells by IL-17 and the underlying mechanisms.
Oncogene. 36:1256–1264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mantovani A, Barajon I and Garlanda C:
IL-1 and IL-1 regulatory pathways in cancer progression and
therapy. Immunol Rev. 281:57–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anuradha R, Munisankar S, Bhootra Y, Dolla
C, Kumaran P, Nutman TB and Babu S: Modulation of CD4+ and CD8+ T
Cell Function and Cytokine Responses in Strongyloides stercoralis
Infection by Interleukin-27 (IL-27) and IL-37. Infect Immun.
85(pii): e00500–17. 2017.PubMed/NCBI
|
|
19
|
Xu L, Zhu LL, Ye LL, Meng LJ, Liu WQ and
Wang J: Percentages of peripheral blood gammadelta t cells and
regulatory t cells and expression of associated cytokines in
infants with human cytomegalovirus infection. Zhongguo Dang Dai Er
Ke Za Zhi. 20:204–208. 2018.(In Chinese). PubMed/NCBI
|
|
20
|
Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X,
Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated
fibroblasts promotes epithelial-mesenchymal transition and
metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Oncotarget. 8:20741–20750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ and
Hu WH: IL-33 promotes gastric cancer cell invasion and migration
via ST2-ERK1/2 pathway. Dig Dis Sci. 60:1265–1272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kopinski P, Wandtke T, Wedrowska E and
Chorostowska-Wynimko J: Interleukin 27 in bronchoalveolar lavage
fluid in patients with non- small cell lung cancer. Authors' reply.
Pol Arch Intern Med. 128:266–268. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Q, Yu YX, Wang XJ and Wang Z and Wang
Z: Diagnostic accuracy of interleukin-27 between tuberculous
pleural effusion and malignant pleural effusion: A meta-analysis.
Respiration. 95:469–477. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patel MV, Shen Z, Rossoll RM and Wira CR:
IL-27 expression and responsiveness in human uterine epithelial
cells and fibroblasts in vitro and the role of estradiol. J
Interferon Cytokine Res. 38:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu J, Liu JQ, Shi M, Cheng X, Ding M,
Zhang JC, Davis JP, Varikuti S, Satoskar AR, Lu L, et al: IL-27
gene therapy induces depletion of tregs and enhances the efficacy
of cancer immunotherapy. JCI Insight. 3(pii): 987452018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Carlo E, Sorrentino C, Zorzoli A, Di
Meo S, Tupone MG, Ognio E, Mincione G and Airoldi I: The antitumor
potential of Interleukin-27 in prostate cancer. Oncotarget.
5:10332–10341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu L, Meng J, Zhang C, Duan Y, Zhao L,
Wang S and Shan B: Effects on apoptosis and cell cycle arrest
contribute to the antitumor responses of interleukin-27 mediated by
retrovirus in human pancreatic carcinoma cells. Oncol Rep.
27:1497–1503. 2012.PubMed/NCBI
|
|
29
|
Zhou WJ, Chang KK, Wu K, Yang HL, Mei J,
Xie F, Li DJ and Li MQ: Rapamycin synergizes with cisplatin in
antiendometrial cancer activation by improving IL-27-stimulated
cytotoxicity of NK cells. Neoplasia. 20:69–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z, Zhou B, Zhang K, Song Y, Zhang L
and Xi M: IL-27 suppresses SKOV3 cells proliferation by enhancing
STAT3 and inhibiting the Akt signal pathway. Mol Immunol.
78:155–163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao JY, Yin HS, Li HS, Yu XQ and Han X:
Interleukin-27 augments the inhibitory effects of sorafenib on
bladder cancer cells. Braz J Med Biol Res. 50:e62072017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Z, Liu JQ, Talebian F, Wu LC, Li S and
Bai XF: IL-27 enhances the survival of tumor antigen-specific CD8+
T cells and programs them into IL-10-producing, memory
precursor-like effector cells. Eur J Immunol. 43:468–479. 2013.
View Article : Google Scholar : PubMed/NCBI
|
